HanAll Biopharma
David Hernandez has a diverse and extensive work experience in the field of clinical operations and development. David started their career as a Research Coordinator at NORTH SHORE LIJ- ZUCKER HILLSIDE HOSPITAL in 1999 and later moved to Rutgers New Jersey Medical School, where they worked as a Research Coordinator, responsible for coordinating clinical studies in psychiatry/CNS.
David then joined Eisai as a Clinical Project Coordinator in 2005 before transitioning to Hoffmann-La Roche as a Clinical Operations Associate, where they managed clinical trials in type 2 diabetes. In 2007, they joined LifeCycle Pharma as a Clinical Study Manager.
From 2008 to 2016, David worked at Sunovion Pharmaceuticals Inc., starting as a Clinical Project Manager and then progressing to become a Manager, Clinical Development. In these roles, they managed various clinical trials in CNS/psychiatry, leading cross-functional teams and overseeing vendors to ensure successful execution of global programs.
In 2015, David joined Dainippon Sumitomo Pharma as an Associate Director Clinical Operations, where they were involved in integrating clinical operations in Japan with global operations and providing training and recommendations for optimization.
Further, David joined Healthcare Business of Merck in 2016 and held the position of Head of Clinical Operations - Asian R&D Hubs. David later became the Head of Clinical Operations Japan, leading a team and implementing an operating model that improved trial execution in Japan.
Currently, David is working at HanAll Biopharma as the Vice President, Head of Clinical Development Operations. In this role, they are responsible for establishing the Clinical Operations function, building infrastructure, hiring talent, and selecting service providers to support clinical development at HanAll.
Throughout their career, David has demonstrated expertise in clinical trial management, CRO oversight, cross-functional collaboration, and ensuring high-quality trial execution.
David Hernandez attended Brooklyn Technical High School from 1988 to 1991, where they earned their high school diploma with a focus on Bio-Med. David then went on to Columbia University from 1991 to 1995, where they obtained their Bachelor of Arts degree in Neuroscience.
This person is not in any teams
This person is not in any offices
HanAll Biopharma
HanAll Biopharma (KRX: 009420.KS) is a global biopharmaceutical company with a presence in Korea, the USA, Japan, and Indonesia, with a mission to make meaningful contributions to patients' lives by introducing innovative, impactful medicines to address severe unmet medical needs. HanAll has been operating a portfolio of pharmaceutical products in areas ranging from endocrine, circulatory, and urologic diseases for 50 years. HanAll has also expanded its focus to ophthalmology, immunology, oncology, and neurology to discover and develop innovative medicines for patients with diseases for which there are no effective treatments. Its lead pipeline asset, HL161 (INN: batoclimab), an anti-FcRn antibody, is being developed in Phase 3 and Phase 2 trials worldwide for the treatment of autoimmune diseases, including myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP), and Graves’ disease (GD). Another key asset, HL036 (INN: tanfanercept), a TNF-alpha inhibitor protein, is being evaluated in Phase 3 clinical studies in the US and China for the treatment of dry eye disease.